Journals Highlights

Dr. Nina Isoherranen Named Editor-in-Chief of Drug Metabolism and Disposition

ASPET’s Publications Committee is pleased to announce that Dr. Nina Isoherranen has been selected to succeed Dr. Xinxin Ding as Editor-in-Chief (EIC) of Drug Metabolism and Disposition (DMD). The transition to the new EIC is effective January 1, 2027.

Dr. Isoherranen received her BS and MS in Analytical Chemistry from the Faculty of Science, University of Helsinki, Finland, and her PhD in Pharmaceutical Sciences from the School of Medicine, Hebrew University of Jerusalem, Israel. She continued her training as a Postdoctoral Research Fellow in the Department of Pharmaceutics, University of Washington (UW). In 2004, she joined the faculty of the Department of Pharmaceutics at UW as an Acting Assistant Professor. She was promoted to full Professor with tenure in 2017 and is currently Chair of the Department of Pharmaceutics, UW, and Milo Gibaldi Endowed Chair of Pharmaceutics.

Dr. Isoherranen’s main research interests relate to vitamin A disposition and disease-retinoid interactions, pregnancy-mediated changes in drug disposition, and drug-drug interactions. She has active research ongoing in the areas of pharmacokinetic modeling and PBPK model development relating to predictions of complex drug-drug and disease-drug interactions, and in developing models for renal clearance changes in different physiological states. Recently her laboratory has made significant advances in characterization of drug-protein adducts by mass spectrometry. Her laboratory has been continuously funded by the NIH for the last 20 years. She has trained numerous graduate students, postdocs, PharmD students, and undergraduate students in her laboratory. Dr. Isoherranen has published over 180 peer reviewed manuscripts and eight book chapters, and holds three US patents.

Dr. Isoherranen has held leadership positions in professional societies including being the chair of the Drug Metabolism and Disposition division of American Society of Pharmacology and Therapeutics (ASPET), an ASPET Council member (2022–2025), and a member of ASPET and FASEB science policy committees. She was a member of the ISSX Membership Affairs committee 2015-2020 and ISSX council 2019-2023. At present, she is an Associate Editor of Drug Metabolism and Disposition, and Pharmacology & Therapeutics. She was an Associate Editor of Clinical and Translational Science until 2021 and a member of the editorial board of Scientific Reports. She was also a member (2019–2023) and chair (2021–2023) of the NIH XNDA (currently DBDT) study section.

Dr. Isoherranen has received the UWSOP graduate student mentor award and multiple young investigator and early career awards including the Drug Metabolism Division Early Career Achievement Award by ASPET in 2013 and the ISSX North American New Investigator award in honor of James R. Gillette in 2014. Most recently, she was awarded the ISSX North American Scientific Achievement Award in Honor of Ronald W. Estabrook in 2024, elected as a Fellow of ASPET, and given the Gerhard Levy Lecture at SUNY Buffalo.

We extend our thanks and say farewell to outgoing EIC Dr. Xinxin Ding as he hands over the reins to Dr. Isoherranen.